Advancing Bispecifics for Combination Immunotherapy

First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics:

• What are the types of bispecifics and what are the limitations?
• What are the toxicity related side effects?
• What are teh next steps/levels for bispecifics?
• What does the future hold for bispecifics?

Panelists include:

• Julie Bailis, PhD, Amgen
• Rajkumar Ganesan, PhD, Janssen Research & Development
• David Schaer, PhD, Pfizer

To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com